(3S,7aS)-2-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-3-butylhexahydro-1H-pyrrolo[1,2-c]imidazol-1-one

ID: ALA4868159

PubChem CID: 164622816

Max Phase: Preclinical

Molecular Formula: C24H28N6O

Molecular Weight: 416.53

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCCC[C@@H]1N(Cc2ccc(-c3ccccc3-c3nnn[nH]3)cc2)C(=O)[C@@H]2CCCN12

Standard InChI:  InChI=1S/C24H28N6O/c1-2-3-10-22-29-15-6-9-21(29)24(31)30(22)16-17-11-13-18(14-12-17)19-7-4-5-8-20(19)23-25-27-28-26-23/h4-5,7-8,11-14,21-22H,2-3,6,9-10,15-16H2,1H3,(H,25,26,27,28)/t21-,22-/m0/s1

Standard InChI Key:  XAJAOOPENTZJHO-VXKWHMMOSA-N

Molfile:  

 
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
    6.6025  -20.5952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6014  -21.4225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3161  -21.8354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0326  -21.4220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0298  -20.5916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3144  -20.1824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7441  -21.8326    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7441  -22.6587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4584  -23.0700    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1731  -22.6564    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1692  -21.8272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4543  -21.4196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4503  -20.5959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1156  -20.1081    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.8572  -19.3247    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.0322  -19.3282    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7808  -20.1139    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8880  -20.1829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1716  -20.5909    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.4166  -20.2553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8647  -20.8686    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.2774  -21.5830    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0843  -21.4111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0577  -21.0416    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9728  -21.8627    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7275  -22.1970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7014  -21.9634    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2508  -19.4484    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4668  -19.1917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2972  -18.3843    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5132  -18.1276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4873  -22.3785    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12  7  1  0
  4  7  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 13  2  0
 12 13  1  0
  1 18  1  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 19  1  0
 21 24  1  0
 24 25  1  0
 25 26  1  0
 26 22  1  0
 23 27  2  0
 20 28  1  6
 28 29  1  0
 29 30  1  0
 30 31  1  0
 22 32  1  1
M  END

Alternative Forms

1. Parent:

   

   ALA4868159

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 416.53

Molecular Weight (Monoisotopic): 416.2325

AlogP: 3.86

#Rotatable Bonds: 7

Polar Surface Area: 78.01

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 4.61

CX Basic pKa: 4.75

CX LogP: 3.35

CX LogD: 2.67

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.63

Np Likeness Score: -0.70

References

1. Hernandez-Olmos V, Heering J, Bischoff-Kont I, Kaps A, Rajkumar R, Liu T, Fürst R, Steinhilber D, Proschak E..  (2021)  Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.,  12  (8.0): [PMID:34413955] [10.1021/acsmedchemlett.1c00240]

2. Yokomizo, T T, Kato, K K, Terawaki, K K, Izumi, T T and Shimizu, T T.  2000-08-07  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders.  [PMID:10934230]

3. Iizuka, Yoshiko Y and 5 more authors.  2005-07-01  Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes.  [PMID:15866883]

4. Okuno, Toshiaki and 5 more authors.  2008-04-14  12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2.  [PMID:18378794]

Source

Source(1):

• Scientific Literature